Detail akcie Catalent online

Business Summary: Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
Financial Summary: BRIEF: For the six months ended 31 December 2023, Catalent Inc revenues decreased 8% to $2.01B. Net loss totaled $965M vs. income of $81M. Revenues reflect Biologics segment decrease of 20% to $886M, United States segment decrease of 9% to $1.3B, Europe segment decrease of 5% to $598M. Net loss reflects Interest Exp-Net of Capitalized Interest increase of 57% to $124M (expense), Other Operating Expense increase from $2M to $36M (expense).